Immunocore (NASDAQ:IMCR) Upgraded by Wall Street Zen to Buy Rating

Wall Street Zen upgraded shares of Immunocore (NASDAQ:IMCR) from a hold rating to a buy rating in a report published on Saturday morning.

Several other research analysts have also weighed in on IMCR. Mizuho set a $38.00 price target on Immunocore in a research report on Thursday, February 19th. Jefferies Financial Group lowered Immunocore from a “buy” rating to a “hold” rating and lowered their price target for the stock from $48.00 to $33.00 in a research report on Monday, March 16th. HC Wainwright restated a “buy” rating and issued a $100.00 price target on shares of Immunocore in a research note on Monday, April 20th. Weiss Ratings restated a “sell (e+)” rating on shares of Immunocore in a research note on Tuesday, April 21st. Finally, Zacks Research cut Immunocore from a “hold” rating to a “strong sell” rating in a research note on Monday, April 27th. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $57.75.

Immunocore Stock Down 3.4%

NASDAQ:IMCR opened at $29.58 on Friday. The firm has a market capitalization of $1.50 billion, a price-to-earnings ratio of -53.78 and a beta of 0.74. Immunocore has a twelve month low of $27.44 and a twelve month high of $40.71. The stock’s 50 day moving average price is $30.87 and its two-hundred day moving average price is $33.32. The company has a quick ratio of 4.01, a current ratio of 4.18 and a debt-to-equity ratio of 1.00.

Immunocore (NASDAQ:IMCR) last posted its quarterly earnings results on Wednesday, May 6th. The company reported $0.25 earnings per share for the quarter, topping the consensus estimate of ($0.26) by $0.51. The firm had revenue of $106.68 million for the quarter, compared to analyst estimates of $145.15 million. Immunocore had a negative return on equity of 7.07% and a negative net margin of 6.68%.The business’s quarterly revenue was up 13.6% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.10 EPS. Equities research analysts expect that Immunocore will post -0.5 earnings per share for the current fiscal year.

Insider Activity at Immunocore

In related news, insider David M. Berman sold 5,965 shares of the stock in a transaction on Wednesday, February 18th. The stock was sold at an average price of $32.35, for a total value of $192,967.75. Following the sale, the insider owned 5,859 shares in the company, valued at approximately $189,538.65. This represents a 50.45% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Bahija Jallal sold 11,474 shares of the stock in a transaction on Wednesday, February 18th. The shares were sold at an average price of $32.35, for a total value of $371,183.90. Following the completion of the sale, the chief executive officer owned 12,343 shares in the company, valued at approximately $399,296.05. This trade represents a 48.18% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders have sold 19,137 shares of company stock worth $619,082. Company insiders own 10.40% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in IMCR. Royal Bank of Canada grew its holdings in Immunocore by 45.1% in the 1st quarter. Royal Bank of Canada now owns 44,011 shares of the company’s stock valued at $1,306,000 after buying an additional 13,689 shares in the last quarter. Geode Capital Management LLC grew its holdings in Immunocore by 40.1% in the 2nd quarter. Geode Capital Management LLC now owns 52,001 shares of the company’s stock valued at $1,632,000 after buying an additional 14,877 shares in the last quarter. Marshall Wace LLP grew its holdings in Immunocore by 425.8% in the 2nd quarter. Marshall Wace LLP now owns 146,610 shares of the company’s stock valued at $4,601,000 after buying an additional 118,728 shares in the last quarter. Sei Investments Co. acquired a new position in Immunocore in the 2nd quarter valued at $983,000. Finally, Cubist Systematic Strategies LLC grew its holdings in Immunocore by 108.0% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 142,757 shares of the company’s stock valued at $4,480,000 after buying an additional 74,128 shares in the last quarter. 84.50% of the stock is owned by institutional investors and hedge funds.

More Immunocore News

Here are the key news stories impacting Immunocore this week:

• Positive Sentiment: HC Wainwright raised its earnings outlook for Immunocore across several periods, including FY2027, FY2028, and quarter-by-quarter estimates for 2027, while maintaining a Buy rating and $100 price target. Article Title
• Positive Sentiment: Zacks Research upgraded Immunocore from strong sell to strong-buy, signaling improved sentiment toward the stock. Article Title
• Neutral Sentiment: Investor attention also appears to be on Immunocore’s recent Q1 2026 results and new KIMMTRAK survival data, which may be influencing valuation views rather than driving a fresh company-specific catalyst. Article Title

About Immunocore

Immunocore plc is a clinical‐stage biotechnology company focused on the development of novel immunotherapies that harness the body’s own T‐cell response to treat cancer and infectious diseases. The company’s proprietary ImmTAC (immune mobilising monoclonal T‐cell receptors against cancer) platform utilizes engineered, soluble T‐cell receptor (TCR) molecules designed to recognise intracellular peptide–HLA complexes. By redirecting and activating T cells against disease‐associated targets, Immunocore aims to address malignancies and persistent viral infections with high unmet medical need.

The company’s most advanced candidate, tebentafusp, is a bispecific ImmTAC molecule that targets gp100, a melanoma‐associated antigen, and has received regulatory approval for the treatment of metastatic uveal melanoma.